NSCLC patients received anti‐CTLA4 antibody may have beneficial effects from the circulating T cells activation, but anti‐CTLA4 antibody also promotes NSCLC cell proliferation via the tumour cell‐intrinsic CTLA4. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.